Medpace raises FY26 guidance after Q2 revenue grows 17.2%, driven by strong backlog and customer prepayments.

Medpace Holdings reported a 17.2% revenue increase to $707.3 million in Q2, with improved EBITDA margins despite pass-through costs. The company raised its full-year 2026 guidance for revenue, EBITDA, and EPS, supported by customer prepayments that fund operations and share buybacks. This strategy helps sustain EPS growth and cushions cash flow volatility amid a biotech funding rebound. While Medpace trades at a premium due to net-cash and customer-funded growth, risks include cancellations, M&A exposure, and reliance on key personnel.

Medpace Holdings trades at USD 613.43 on Pluang as of Oct 14, 2026 01:31 WIB, down 1.07% in one day. The stock holds a market cap of $17.32 billion and a 52-week high of $630.19. Pluang investors show full buy interest with 100% buy orders and a typical hold time of 14 days.